Limited pharmacogenetic impact

Pharmacogenomic information on the OneOme RightMed® test cannot be used to help predict patient response in two situations:

  • blue indicator icon   LIMITED PHARMACOGENETIC IMPACT >
    • ●    For these medications, no pharmacogenetic variants demonstrate a significant impact on medication response
  • grey indicator icon   OTHER MEDICATIONS >
    • ●    For these medications, evidence of a gene-drug interaction does not meet OneOme's inclusion criteria OR pharmacogenetic variants not tested by the RightMed test may significantly affect medication response

These medications are available for the provider to review in our online RightMed Advisor, which provides information on their classification and can be evaluated for drug-to-drug interactions.

LIMITED PHARMACOGENETIC IMPACT

For these medications, no pharmacogenetic variants demonstrate a significant impact on medication response. Other types of genetic tests that may guide prescribing (e.g., tumor marker testing, diagnostic, or indication-establishing testing) are not taken into account. They are included on the RightMed reports and in the RightMed Advisor in the limited pharmacogenetic impact category. They are classified into a blue category and indicated by indicator icon.

By providing information on these drugs, OneOme helps providers make a more informed decision even if these medications are not dependent on the patient’s genotype.

This saves providers the time and resources necessary for evaluating the available pharmacogenomic information on these medications through analyzing and compiling pertinent clinical literature.

Montelukast (Singulair®)
Naloxone (Evzio®, Narcan®)
Dalteparin (Fragmin®)
Enoxaparin (Lovenox®)
Prasugrel (Effient®)
Tirofiban (Aggrastat®)
Alirocumab (Praluent®)
Colesevelam (Welchol®)
Digoxin (Digitek®, Digox®, Lanoxin®)
Gemfibrozil (Lopid®)
Lisinopril (Prinivil®, Zestril®)
Nitroglycerin (Minitran®, Nitrostat®)
Sotalol (Betapace®, Sorine®)
Spironolactone (Aldactone®)
Telmisartan (Micardis®)
Ibandronate (Boniva®)
Insulin aspart (Novolog®)
Insulin aspart protamine/Insulin aspart (Novolog® mix)
Insulin aspart/Insulin degludec (Ryzodeg® 70/30)
Insulin degludec (Tresiba®)
Insulin detemir (Levemir®)
Insulin glargine (Lantus®, Toujeo®)
Insulin glulisine (Apidra®)
Insulin lispro (Humalog®)
Insulin lispro protamine/Insulin lispro (Humalog® mix)
Insulin NPH (Humulin® N, Novolin® N)
Insulin NPH/Insulin regular (Humulin® 70/30, Novolin® 70/30)
Insulin regular (Humulin® R, Novolin® R)
Insulin regular (oral inhalation) (Afrezza®)
Levothyroxine (Levoxyl®, Synthroid®)
Metformin (Fortamet®, Glucophage®)
Pamidronate (Aredia®)
Risedronate (Actonel®, Atelvia®)
Vasopressin (Vasostrict®)
Sapropterin (Kuvan®)
Sodium phenylbutyrate (Buphenyl®)
Velaglucerase alfa (Vpriv®) testtube icon
Afatinib (Gilotrif®) testtube icon
Alemtuzumab (Campath®, Lemtrada®) testtube icon
Darbepoetin alfa (Aranesp®)
Epoetin alfa (Epogen®, Procrit®)
Ibritumomab (Zevalin®) testtube icon
Obinutuzumab (Gazyva®) testtube icon
Ofatumumab (Arzerra®) testtube icon
Panitumumab (Vectibix®) testtube icon
Pertuzumab (Perjeta®) testtube icon
Mycophenolate sodium (Myfortic®)
Atovaquone (Mepron®)
Cefdinir (Omnicef®)
Ceftriaxone (Rocephin®)
Fluconazole (Diflucan®)
Flucytosine (Ancobon®)
Levofloxacin (Levaquin®)
Meropenem (Merrem®)
Moxifloxacin (Avelox®)
Nystatin (Bio-Statin®)
Piperacillin (Pipracil®)
Posaconazole (Noxafil®)
Vancomycin (Vancocin®)
Zanamivir (Relenza®)
Gabapentin (Neurontin®)
Levetiracetam (Keppra®)
Memantine (Namenda®)
Pramipexole (Mirapex®)
Pregabalin (Lyrica®)
Succimer (Chemet®)
Vigabatrin (Sabril®)
Desvenlafaxine (Pristiq®)
Lithium (Lithobid®)
Milnacipran (Savella®)
Paliperidone (Invega®)
Varenicline (Chantix®)
Belimumab (Benlysta®)
Temazepam (Restoril®)



ADDITIONAL TESTING

test tube icon : According to the FDA drug label, additional laboratory testing may be indicated.

Other medications

For these medications, evidence of a gene-drug interaction does not meet OneOme's inclusion criteria OR pharmacogenetic variants not tested by the RightMed test may significantly affect medication response. Additional information may be found in the RightMed Advisor in the Other medications category. They are classified into a gray category and indicated by gray med icon.

As OneOme continuously reviews medications, information regarding the impact associated genes may have on these medications will be added to the pharmacogenomics database. OneOme strives to provide relevant information that empowers providers in their therapeutic decisions.